The redemption of benefits related to the drug-related 'Choline Alfoscerate', a brain function improvement agent, has been extended until April 12th.

The NHIS has been negotiating benefits redemption of 230 items from 130 companies including Choline Alfoscerate in accordance with the order of the MOHW on December 14 last year.

In addition to 227 Choline Alfoscerate, Alvogen Korea's Ateroid, Chodang's Mesocan 50mg, and Ajou's Aju Vesseldue-F were included in the benefit redemption negotiations.

In the first round of negotiations, which took place from December 14, 2020 to February 10, 2021, about half of Choline Alfoscerate products, Ateroid, and Mesocan were decided